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Abstract
Background:  Cholecystokinin (CCK) concentrations in plasma have been shown to be
significantly higher in colectomised subjects compared to healthy controls. This has been ascribed
to reduced inhibition of CCK release from colon. In an earlier study CCK in all but one woman
who was colectomised, induced release of oxytocin, a peptide present throughout the
gastrointestinal (GI) tract. The aim of this study was thus to examine if colectomised women had
a different oxytocin response to CCK compared to healthy controls.
Methods: Eleven women, mean age 34.4 ± 2.3 years, who had undergone colectomy because of
ulcerative colitis or constipation were studied. Eleven age-matched healthy women served as
controls. All subjects were fasted overnight and given 0.2 µg/kg body weight of CCK-8 i.v. in the
morning. Samples were taken ten minutes and immediately before the injection, and 10, 20, 30, 45,
60, 90 and 120 min afterwards. Plasma was collected for measurement of CCK and oxytocin
concentrations.
Results: The basal oxytocin and CCK concentrations in plasma were similar in the two groups.
Intravenous injection of CCK increased the release of oxytocin from 1.31 ± 0.12 and 1.64 ± 0.19
pmol/l to 2.82 ± 0.35 and 3.26 ± 0.50 pmol/l in controls and colectomised women, respectively (p
< 0.001). Given the short half-life of CCK-8 in plasma, the increased concentration following
injection could not be demonstrated in the controls. On the other hand, in colectomised women,
an increase of CCK in plasma was observed for up to 20 minutes after the injection, concentrations
increasing from 1.00 ± 0.21 to a maximum of 1.81 ± 0.26 pmol/l (p < 0.002).
Conclusion: CCK stimulates the release of oxytocin in women. There is no difference in plasma
concentrations between colectomised and controls. However, colectomy seems to reduce the
metabolic clearance of CCK. The hyperCCKemia in patients who had undergone colectomy is
consequently not only dependent on CCK release, but may also depend on reduced clearance.
Background
The gut hormone cholecystokinin (CCK) is synthesised in
endocrine I cells in the mucosa of the upper small intes-
tine [1] and is released into the blood after ingestion of
fatty and protein-rich meals [2]. CCK has various effects
on the gastrointestinal (GI) tract and acts on afferent vagal
nerves [3], neurons of the myenteric plexus [4], and
directly on muscle cells [5]. It is also synthesised in central
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neurons including hypothalamic, oxytocinergic neurons
[6]. Circulating CCK is degraded in several sites, namely
the kidney, liver and gut [7,8].
Oxytocin is synthesised in the supraoptic and paraven-
tricular nuclei of the hypothalamus as part of a larger pre-
cursor polypeptide [9]. While the main effects are in the
myoepithelial cells and uterine smooth muscle in the
responses associated with the milk ejection reflex and par-
turition, the possibility has been raised that oxytocin also
contributes to control of the GI motility [10,11]. Both
exogenous and food-stimulated endogenous CCK stimu-
lates the pituitary secretion of oxytocin in the rat through
CCK-receptors on afferent vagal neurons [12]. In hypoth-
alamus, both parvocellular neurons projecting to the dor-
sal vagal complex, and magnocellular neurons projecting
to the pituitary, secrete oxytocin in response to CCK [13].
We have recently found that CCK also leads to oxytocin
release in healthy women [14]. However, one of the
women included was colectomised, and she was the only
one who had no release of oxytocin in response to CCK
[14], although colectomy leads to higher concentrations
of CCK in plasma [15-17]. We have found mRNA for oxy-
tocin and its receptor throughout the GI tract [18], as well
as the fully expressed proteins (unpublished observation).
We do not know if this has an autocrine and/or paracrine
role in the gut, or if it also is released into the blood as a
hormone. The aim of this study was therefore to examine
if women who had performed a colectomy, had a different
oxytocin response to CCK than otherwise healthy women
with an intact GI tract.
Methods
Subjects
Eleven women from the Departments of Medicine and
Surgery at Malmö University Hospital (mean age 34.4 ±
2.3 years, range 22–42 years) were studied. They had all a
history of colectomy. Two were colectomised because of
slow transit constipation (STC) and had undergone a sub-
total colectomy with the creation of ileo-rectal anastomo-
sis. Proctocolectomy with ileal pouch-anal anastomosis
had been performed in seven of them because of ulcera-
tive colitis, and one because of familial multiple polypo-
sis. The last patient has an ileostomy after subtotal
colectomy, saving the rectum, because of ulcerative colitis.
Thus, the subjects were cured from their original condi-
tions. The time interval between the proctocolectomy/
colectomy and this study was 10–149 months, with a
mean of 48.5 ± 12.6 months. Eleven age-matched healthy
women with preserved GI tract served as controls. Physical
examination and laboratory routine screening were all
within normal limits in both groups. The body weight was
68.7 ± 5.8 kg in the patients and 73.8 ± 6.1 kg in the con-
trols. No drugs and no oral contraceptives or other hor-
monal treatments were allowed in either group. The
experiments were performed at no specific stage of the
menstrual cycle. None of the included subjects had partic-
ipated in our former study [14].
Protocols
The protocols were approved by the local Ethics commit-
tee at the University of Lund, and written informed con-
sent was obtained from all subjects before the study was
started. The possibility of pregnancy was excluded in all
women.
Experimental procedure
All subjects were fasted overnight. In the morning they
were given 0.2 µg/kg body weight of cholecystokinin
octapeptide (CCK-8) (Clinalfa, Switzerland) as an intrave-
nous injection. This bolus was chosen as it was the only
dose giving raise to a weak, but not significant, oxytocin
release in an earlier study [19]. Blood samples were taken
through an intravenous catheter 10 min before and
immediately before the injection, and 10, 20, 30, 45, 60,
90 and 120 min after the injection.
Hormone analysis
All blood samples consisted of 8.0 ml whole blood drawn
into iced heparinised tubes. The plasma was separated
and frozen at -20°C immediately after the experiment.
Oxytocin was measured as described by Balment et al [20]
using the Fourth International Standard for oxytocin (76/
575). The lower limit of detection for this assay was 0.1
pmol/l with intra-assay and interassay variations of 5.4
and 11.8 %, respectively, at 2.5 pmol/l. The hormone was
extracted from plasma using C 18 Sep Pak Columns
(Waters Associates Ltd., Northwick, Middx., U.K.). The
concentrations of CCK in plasma were measured using a
highly specific and accurate radioimmunoassay as previ-
ously described [21]. The limit of detection for his assay is
0.1 pmol/l with intra-assay and interassay variations of
less than 5 % and 15 %, respectively, at both 3.7 and 15
pmol/l concentrations.
Statistical analysis
The values are expressed as mean ± standard error of the
mean (SEM). The basal value is the mean of the two fast-
ing values. The peak value is the mean of the highest con-
centration in every subject after the injection. The total
plasma CCK and oxytocin response was assessed by calcu-
lating the area under the plasma concentration time curve
(AUC). The Kruskal-Wallis followed by Wilcoxon signed
ranks test were used for assessment of the significance of
the differences within and between the two groups. The
Spearman rank test was used for calculating the correla-
tion between CCK and oxytocin concentrations in
plasma. Probabilities of less than 0.05 were considered
significant.BMC Gastroenterology 2004, 4:25 http://www.biomedcentral.com/1471-230X/4/25
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Results
Plasma oxytocin concentrations
The basal oxytocin concentration in plasma was similar in
the two groups. The concentration was stable before the
start of the experiments. Injection of CCK-8 led to an
increase of the oxytocin secretion compared to basal val-
ues in both groups (p < 0.001) (Table 1). The increase in
plasma concentration of oxytocin was observed after 10
min and persisted throughout the study. The highest con-
centration was found after 20 min (Fig 1). There was no
difference of the AUC between the two groups, neither
there was any difference between each time point studied
(Fig 1).
Plasma cholecystokinin concentrations
There was a tendency towards higher basal CCK concen-
tration in patients, although not significant (Table 1 and
Fig 2). CCK-8 has a half-life in plasma of about < 1 min
(8). Therefore, no increase in plasma CCK could be
detected in the control group after the intravenous injec-
tion of CCK-8 (Table 1). However, in colectomised
women, an increase in plasma CCK concentrations was
found after the injection compared to basal values (p <
0.002). The difference of peak value between the groups
was significant (p < 0.04) (Table 1). The AUC differed sig-
nificantly between the two groups (p < 0.04), but no dif-
ference was observed between values at each time point
studied (Fig 2).
There was no correlation between CCK and oxytocin con-
centrations (data not shown). Neither was there any dif-
ference in CCK and oxytocin concentrations between
patients with different diagnosis and those who had rec-
tum saved or resected (data not shown).
Discussion
This study shows for the first time that CCK-8 increases
the secretion of oxytocin in women. We have previously
shown that exogenous CCK-33 and -39, and a fatty meal
with endogenous CCK release, led to enhanced concentra-
tions of oxytocin in plasma [14]. One patient in that study
was colectomised, and she was the only one in whom no
increase in oxytocin release was seen after CCK stimula-
tion. This observation prompted the present study. In this
study, there was no difference in plasma concentrations of
oxytocin between colectomised and healthy controls.
Thus, the oxytocin secreted into the blood after CCK stim-
ulation seems not to origin from the colon. The oxytocin
recently found in the colon may participate in autocrine
and/or paracrine regulation of the gut while having no
endocrine effects [18]. The patient group examined in this
study was not homogenous, but it was not possible to
include enough young women with colectomy after ulcer-
ative colitis. We have earlier described the presence of oxy-
tocin and its receptor throughout the gut, without any
efforts to quantify the expression [18]. Only the effect of
colon on plasma concentrations of oxytocin was meas-
ured in the present study. We do not know from this study
if oxytocin from some other part of the gut is released into
the plasma. It is difficult to conduct an experiment to
examine the origin from the oxytocin release. CCK acts on
receptors on afferent vagal nerves to stimulate the oxy-
tocin release from the pituarity [12], and these receptors
Table 1: Basal and peak plasma values of cholecystokinin (CCK) 
and oxytocin
CCK (pmol/l) N = 11 Oxytocin (pmol/l) N = 11
Controls
Basal 0.7 ± 0.1 1.3 ± 0.1
Peak 0.9 ± 0.1 2.8 ± 0.4***
Patients
Basal 1.0 ± 0.2 1.6 ± 0.2
Peak 1.8 ± 0.3**+ 3.3 ± 0.5***
Values are expressed as mean value ± standard error of the mean 
(SEM). Comparisons are made within groups; ** = p < 0.01, *** = p < 
0.001, and between groups; + = p < 0.05. Wilcoxon signed rank test. 
The basal value is the mean of the two fasting values. The peak value is 
the mean of the highest concentration in every subject after the 
injection.
The plasma concentration of oxytocin before and at different  time points after an injection of 0.2 µg/kg body weight of  cholecystokinin-8 (CCK-8) Figure 1
The plasma concentration of oxytocin before and at different 
time points after an injection of 0.2 µg/kg body weight of 
cholecystokinin-8 (CCK-8). There were 11 subjects in each 
group. Values are given as mean and standard error of the 
mean (SEM). There was no difference between the groups 
neither when calculating values at different time points stud-
ied nor the area under the curve (AUC). Wilcoxon signed 
rank test.   = control, = patient.
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are present throughout the GI tract [3-5]. Therefore it is
not possible to use CCK-receptor antagonists to distin-
guish between central or local CCK effects.
CCK has been shown to stimulate oxytocin secretion in
mammals in many studies [12-14]. However, in a previ-
ous study, intravenous injection of CCK-8, in the same
dose as in our study, did not increase the concentration of
oxytocin in plasma [19]. This may depend on methodo-
logical differences. Another possible explanation to the
difference is the effect of gonadal hormones on the regu-
lation of the oxytocin release from the posterior pituitary
gland. In our study, only women were included, whereas
Miaskiewicz et al [19] examined 13 men and one woman.
Orally administered estrogen stimulates oxytocin secre-
tion, and progesterone also affects release [22]. Lower
plasma levels of these hormones in men may explain the
absence of increased oxytocin secretion in men. In addi-
tion, one study has shown that testosterone inhibits the
secretion of oxytocin from the pituitary gland [23].
Oxytocin is present in plasma in men, although at lower
concentrations [24,25], and shows a circadian rythm [26].
Oxytocin may have similar effects on the GI tract in men
and women, although the plasma concentrations differ.
The effects of oxytocin have been only rudimentary exam-
ined. However, oxytocin has in one study been shown to
enhance gastric emptying [10], and in a yet unpublished
study, we have found that an oxytocin-receptor antagonist
delayed the gastric emptying rate (unpublished observa-
tion). Further, we have demonstrated increased colonic
peristaltis after oxytocin stimulation in healthy women
[11]. Our finding of oxytocin release in response to a meal
[14], and the presence of oxytocin receptors on the cells
that regulate the gut motility (unpublished observation),
suggest oxytocin to play a physiological role in the GI
function.
Several studies have reported that after colectomy in dif-
ferent species there are higher concentrations of CCK in
plasma, both basal and postprandial, compared to
healthy controls [15-17]. It has been suggested that this is
due to depletion of an inhibitory factor of CCK secretion
which is released from the colon. Peptide YY (PYY) is
secreted from distal ileum and colon, and CCK is known
to stimulate PYY secretion from the hindgut [27-29]. PYY
then inhibits further CCK secretion [30,31]. As PYY is
secreted from the hindgut, this peptide is substantially
reduced after colectomy [26]. Thus, the reduced PYY con-
centration may explain the hyperCCKemia. In this study,
the elevated CCK concentrations in the group of colect-
omised women were not due to increased secretion of
CCK, as CCK was injected exogenously. Instead, the
hyperCCKemia in the group of colectomised patients
seems to be due to reduced degradation of the peptide
injected. CCK is degraded in the kidney, liver and gut
[7,8]. Our hypothesis is that PYY could contribute to the
degradation as well as the secretion of CCK. Receptors for
PYY have been found in the kidney and on hepatocytes,
and PYY influences the renal and hepatocyte metabolism
[32-34]. Alternatively, the different CCK concentrations
could be due to reduced degradation in the colon in addi-
tion to the kidney and liver, as CCK-8 has been shown to
be degraded in the gut in pigs [8]. It remains to be deter-
mined which mechanism contributes most to the hyperC-
CKemia observed after colectomy; increased CCK
secretion, or decreased clearance. In the present study, the
basal levels of CCK did not differ significantly in colect-
omised, as observed in earlier studies [15-17].
CCK has a wide range of effects on the GI tract. Three
physiological effects on gut motility have been identified;
contraction of the gallbladder [2], relaxation of the
sphincter Oddi [35] and inhibition of gastric emptying
[2]. Its role on colonic motility is controversial. While Bar-
one et al [36] were able to demonstrate contractions,
Niederau et al could find no effect of CCK [37]. Further,
CCK increases pancreatic enzyme secretion [2]. It is not
The plasma concentration of cholecystokinin (CCK) before  and at different time points after an injection of 0.2 µg/kg  body weight of CCK-8 Figure 2
The plasma concentration of cholecystokinin (CCK) before 
and at different time points after an injection of 0.2 µg/kg 
body weight of CCK-8. There were 11 subjects in each 
group. Values are given as mean and standard error of the 
mean (SEM). When calculating the area under the curve 
(AUC), there was a significantly increased AUC in the colect-
omised subjects compared to controls (p < 0.04). No differ-
ence was seen between the groups when comparing values at 
each time point. Wilcoxon signed rank test.   = control, = 
patient.
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known if the hyperCCKemia observed in colectomised
patients [15-17] has any impact on GI motility or health.
Conclusions
CCK stimulates the release of oxytocin in women, proba-
bly via an effect on the neurohypophysial system. There is
no difference in plasma concentrations between colect-
omised women and women with intact GI tract. The
hyperCCKemia observed in patients who have undergone
colectomy is dependent not only on an increase in CCK
release, but may also depend on a reduced degradation. It
was beyond the aim of our study to determine the clear-
ance of CCK. However, this should be evaluated further.
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